Ocular adverse events with immune checkpoint inhibitors
Purpose: To quantify the risk of ocular adverse events with immune checkpoint inhibitors (ICIs) as reported to the Food and Drug Administration (FDA). Methods: Disproportionality analysis using data from U.S. FDA's Adverse Events Reporting System (FAERS) database 2003 to 2018. Data from pharmac...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wolters Kluwer Medknow Publications
2019-09-01
|
| Series: | Journal of Current Ophthalmology |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2452232519300885 |